{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:47:34Z","timestamp":1788241654076,"version":"build-2803163510"},"posted":{"date-parts":[[2026,1,30]]},"group-title":"In Review","reference-count":53,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,12,8]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  <bold>Background:<\/bold>\n                  Although hypermobile Ehlers-Danlos syndrome (hEDS) and hypermobility spectrum disorders (HSD) are inherited disorders expected to display a 1:1 sex ratio, most studies report a strong female dominance. This study analyzed sex differences in 122 self-reported symptoms and comorbidities in patients diagnosed with hEDS or HSD using the 2017 criteria.\n                  <bold\/>\n                  <bold>Methods:<\/bold>\n                  Self-reported data was obtained from November 1, 2019, to April 25, 2025, (\n                  <italic>n<\/italic>\n                  =2,451) from an Intake Questionnaire of adult (\u226418 years old) patients diagnosed with hEDS or HSD at the EDS Clinic at Mayo Clinic Florida and analyzed by sex.\n                  <bold\/>\n                  <bold>Results:<\/bold>\n                  We found that 90.6% (\n                  <italic>n<\/italic>\n                  =575) of hEDS patients were female and 9.4% (\n                  <italic>n<\/italic>\n                  =60) were male, with a sex ratio of 9.6:1 female-to-male, while 95.2% (\n                  <italic>n<\/italic>\n                  =1,728) of HSD patients were female and 4.8% (\n                  <italic>n<\/italic>\n                  =88) were male, with a sex ratio of 19.6:1 female-to-male. Females were older than males: hEDS 35 vs. 28 years of age (\n                  <italic>p<\/italic>\n                  &lt;0.001), HSD 34 vs. 31 years of age (\n                  <italic>p<\/italic>\n                  =0.004). Overall, females self-reported more symptoms\/comorbidities than males: hEDS 31\/122 (25.4%), HSD 59\/122 (48.4%). In contrast, only 5\/122 (4.1%) symptoms\/comorbidities were self-reported more often in males including attention deficit disorder\/attention deficit hyperactivity disorder, delay in developmental milestones, snoring, autism spectrum disorder, and obstructive sleep apnea. Females with HSD had more mast cell-related symptoms (i.e., hives\n                  <italic>p<\/italic>\n                  &lt;0.001) which were reflected in higher mast cell scores than males (\n                  <italic>p<\/italic>\n                  &lt;0.001). Patients with higher mast cell scores also had higher serum levels of total IgE (\n                  <italic>p<\/italic>\n                  =0.029). More females with HSD were diagnosed with fibromyalgia (\n                  <italic>p<\/italic>\n                  &lt;0.001) and reported symptoms associated with autonomic dysfunction than males. Aside from abuse, which was higher in females (hEDS\n                  <italic>p<\/italic>\n                  =0.039, HSD\n                  <italic>p<\/italic>\n                  &lt;0.001), few sex differences were reported for psychological symptoms\/comorbidities. In support for the idea that elevated mast cell activity in females may lead to extracellular matrix remodeling that promotes hypermobility, females with hEDS\/HSD had greater serum collagen-4\u03b11 (\n                  <italic>p<\/italic>\n                  &lt;0.0001) and fibronectin (\n                  <italic>p<\/italic>\n                  =0.015) than males by ELISA.\n                  <bold\/>\n                  <bold>Conclusions:<\/bold>\n                  Females with hEDS and HSD report a higher burden of symptoms\/comorbidities than males, providing a possible explanation for fewer males being reported in demographic data. Sex differences in symptoms\/comorbidities may reflect sex differences in pathogenic drivers of disease.\n                <\/p>","DOI":"10.21203\/rs.3.rs-8310986\/v1","type":"posted-content","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T13:10:42Z","timestamp":1769778642000},"source":"Crossref","is-referenced-by-count":2,"title":["Sex differences in self-reported symptoms and comorbidities associated with hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders: A retrospective study"],"prefix":"10.21203","author":[{"given":"Frances C.","family":"Wilson","sequence":"first","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek J.","family":"Zangerle","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley A.","family":"Darakjian","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Bhutani","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica J.","family":"Fliess","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica M.","family":"Gehin","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max W.","family":"Strandes","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charwan","family":"Hamilton","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna J.","family":"Sledge","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David O.","family":"Hodge","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin W.E.","family":"Wang","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paldeep S.","family":"Atwal","sequence":"additional","affiliation":[{"name":"Atwal Clinic, West Palm Beach"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley M.","family":"Zeman","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrisandra L.","family":"Shufelt","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa N.","family":"Gajarawala","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn A.","family":"Bruno","sequence":"additional","affiliation":[{"name":"University of Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dacre R.T.","family":"Knight","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DeLisa","family":"Fairweather","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/978-94-007-7893-1_9","article-title":"The Ehlers-Danlos syndrome","volume":"802","author":"Malfait F","year":"2014","unstructured":"Malfait F, De Paepe A. The Ehlers-Danlos syndrome. Adv Exp Med Biol. 2014;802:129\u201343.","journal-title":"Adv Exp Med Biol"},{"issue":"8","key":"ref2","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1002\/acr.21979","article-title":"Modest association of joint hypermobility with disabling and limiting musculoskeletal pain: results from a large-scale general population-based survey","volume":"65","author":"Mulvey MR","year":"2013","unstructured":"Mulvey MR, Macfarlane GJ, Beasley M, Symmons DP, Lovell K, Keeley P, et al. Modest association of joint hypermobility with disabling and limiting musculoskeletal pain: results from a large-scale general population-based survey. Arthritis Care Res (Hoboken). 2013;65(8):1325\u201333.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ajmg.c.31538","article-title":"Hypermobile Ehlers-Danlos syndrome (a.k.a. Ehlers-Danlos syndrome Type III and Ehlers-Danlos syndrome hypermobility type): Clinical description and natural history","volume":"175","author":"Tinkle B","year":"2017","unstructured":"Tinkle B, Castori M, Berglund B, Cohen H, Grahame R, Kazkaz H, et al. Hypermobile Ehlers-Danlos syndrome (a.k.a. Ehlers-Danlos syndrome Type III and Ehlers-Danlos syndrome hypermobility type): Clinical description and natural history. Am J Med Genet C Semin Med Genet. 2017;175(1):48\u201369.","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ajmg.c.31552","article-title":"The 2017 international classification of the Ehlers-Danlos syndromes","volume":"175","author":"Malfait F","year":"2017","unstructured":"Malfait F, Francomano C, Byers P, Belmont J, Berglund B, Black J, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175(1):8\u201326.","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/ajmg.c.31539","article-title":"A framework for the classification of joint hypermobility and related conditions","volume":"175","author":"Castori M","year":"2017","unstructured":"Castori M, Tinkle B, Levy H, Grahame R, Malfait F, Hakim A. A framework for the classification of joint hypermobility and related conditions. Am J Med Genet C Semin Med Genet. 2017;175(1):148\u201357.","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/bmb\/ldad013","article-title":"Placing joint hypermobility in context: Traits, disorders and syndromes","volume":"147","author":"Morlino S","year":"2023","unstructured":"Morlino S, Castori M. Placing joint hypermobility in context: Traits, disorders and syndromes. Br Med Bull. 2023;147(1):90\u2013107.","journal-title":"Br Med Bull"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"751768","DOI":"10.5402\/2012\/751768","article-title":"Ehlers-Danlos syndrome, hypermobility type: An underdiagnosed hereditary connective tissue disorder with mucocutaneous, articular, and systemic manifestations","volume":"2012","author":"Castori M","year":"2012","unstructured":"Castori M. Ehlers-Danlos syndrome, hypermobility type: An underdiagnosed hereditary connective tissue disorder with mucocutaneous, articular, and systemic manifestations. ISRN Dermatol. 2012;2012:751768.","journal-title":"ISRN Dermatol"},{"issue":"3","key":"ref8","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jpainsymman.2009.12.026","article-title":"Pain in Ehlers-Danlos syndrome is common, severe, and associated with functional impairment","volume":"40","author":"Voermans NC","year":"2010","unstructured":"Voermans NC, Knoop H, Bleijenberg G, van Engelen BG. Pain in Ehlers-Danlos syndrome is common, severe, and associated with functional impairment. J Pain Symptom Manage. 2010;40(3):370\u20138.","journal-title":"J Pain Symptom Manage"},{"issue":"4","key":"ref9","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/ajmg.c.31940","article-title":"Mast cell activation disease and immunoglobulin deficiency in patients with hypermobile Ehlers-Danlos syndrome\/hypermobility spectrum disorder","volume":"187","author":"Brock I","year":"2021","unstructured":"Brock I, Prendergast W, Maitland A. Mast cell activation disease and immunoglobulin deficiency in patients with hypermobile Ehlers-Danlos syndrome\/hypermobility spectrum disorder. Am J Med Genet C Semin Med Genet. 2021;187(4):473\u201381.","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1096180","DOI":"10.3389\/fmed.2023.1096180","article-title":"High overlap in patients diagnosed with hypermobile Ehlers-Danlos syndrome or hypermobile spectrum disorders with fibromyalgia and 40 self-reported symptoms and comorbidities","volume":"10","author":"Fairweather D","year":"2023","unstructured":"Fairweather D, Bruno KA, Darakjian AA, Bruce BK, Gehin JM, Kotha A, et al. High overlap in patients diagnosed with hypermobile Ehlers-Danlos syndrome or hypermobile spectrum disorders with fibromyalgia and 40 self-reported symptoms and comorbidities. Front Med (Lausanne). 2023;10:1096180.","journal-title":"Front Med (Lausanne)"},{"issue":"11","key":"ref11","doi-asserted-by":"crossref","first-page":"e031365","DOI":"10.1136\/bmjopen-2019-031365","article-title":"Diagnosed prevalence of Ehlers-Danlos syndrome and hypermobility spectrum disorder in Wales, UK: A national electronic cohort study and case-control comparison","volume":"9","author":"Demmler JC","year":"2019","unstructured":"Demmler JC, Atkinson MD, Reinhold EJ, Choy E, Lyons RA, Brophy ST. Diagnosed prevalence of Ehlers-Danlos syndrome and hypermobility spectrum disorder in Wales, UK: A national electronic cohort study and case-control comparison. BMJ Open. 2019;9(11):e031365.","journal-title":"BMJ Open"},{"issue":"4","key":"ref12","doi-asserted-by":"crossref","first-page":"rkae134","DOI":"10.1093\/rap\/rkae134","article-title":"Similarities and differences in self-reported symptoms and comorbidities between hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders","volume":"8","author":"Darakjian AA","year":"2024","unstructured":"Darakjian AA, Bhutani M, Fairweather D, Kocsis SC, Fliess JJ, Khatib S, et al. Similarities and differences in self-reported symptoms and comorbidities between hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders. Rheumatol Adv Pract. 2024;8(4):rkae134.","journal-title":"Rheumatol Adv Pract"},{"key":"ref13","unstructured":"Hakim AKS, FC, Bloom L, Malfait F, Gandy W, editors. The proportion of people reporting multisystemic morbidities is similar across the Ehlers Danlos syndromes. The 2022 Ehlers-Danlos Society International Symposium on the EDS and HSD 2022; Rome, Italy."},{"issue":"10","key":"ref14","first-page":"1722","article-title":"Severity classes in adults with hypermobile Ehlers-Danlos syndrome\/hypermobility spectrum disorders: A pilot study of 105 Italian patients","volume":"58","author":"Copetti M","year":"2019","unstructured":"Copetti M, Morlino S, Colombi M, Grammatico P, Fontana A, Castori M. Severity classes in adults with hypermobile Ehlers-Danlos syndrome\/hypermobility spectrum disorders: A pilot study of 105 Italian patients. Rheumatology (Oxford). 2019;58(10):1722\u201330.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"ref15","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/ajmg.a.61459","article-title":"Utilization of the 2017 diagnostic criteria for hEDS by the Toronto GoodHope Ehlers-Danlos syndrome clinic: A retrospective review","volume":"182","author":"McGillis L","year":"2020","unstructured":"McGillis L, Mittal N, Santa Mina D, So J, Soowamber M, Weinrib A, et al. Utilization of the 2017 diagnostic criteria for hEDS by the Toronto GoodHope Ehlers-Danlos syndrome clinic: A retrospective review. Am J Med Genet A. 2020;182(3):484\u201392.","journal-title":"Am J Med Genet A"},{"issue":"7","key":"ref16","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/ajmg.a.62197","article-title":"Subtle differences in autonomic symptoms in people diagnosed with hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders","volume":"185","author":"Martinez KL","year":"2021","unstructured":"Martinez KL, Mauss C, Andrews J, Saboda K, Huynh JM, Sanoja AJ, et al. Subtle differences in autonomic symptoms in people diagnosed with hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders. Am J Med Genet A. 2021;185(7):2012\u201325.","journal-title":"Am J Med Genet A"},{"issue":"2","key":"ref17","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/ajmg.a.63426","article-title":"Looking back and beyond the 2017 diagnostic criteria for hypermobile Ehlers-Danlos syndrome: A retrospective cross-sectional study from an Italian reference center","volume":"194","author":"Ritelli M","year":"2024","unstructured":"Ritelli M, Chiarelli N, Cinquina V, Vezzoli M, Venturini M, Colombi M. Looking back and beyond the 2017 diagnostic criteria for hypermobile Ehlers-Danlos syndrome: A retrospective cross-sectional study from an Italian reference center. Am J Med Genet A. 2024;194(2):174\u201394.","journal-title":"Am J Med Genet A"},{"issue":"10","key":"ref18","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s00296-021-04968-3","article-title":"Are patients with hypermobile Ehlers-Danlos syndrome or hypermobility spectrum disorder so different?","volume":"41","author":"Aubry-Rozier B","year":"2021","unstructured":"Aubry-Rozier B, Schwitzguebel A, Valerio F, Tanniger J, Paquier C, Berna C, et al. Are patients with hypermobile Ehlers-Danlos syndrome or hypermobility spectrum disorder so different? Rheumatol Int. 2021;41(10):1785\u201394.","journal-title":"Rheumatol Int"},{"issue":"9","key":"ref19","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1002\/ajmg.a.33585","article-title":"Ehlers-Danlos syndrome hypermobility type and the excess of affected females: Possible mechanisms and perspectives","volume":"152A","author":"Castori M","year":"2010","unstructured":"Castori M, Camerota F, Celletti C, Grammatico P, Padua L. Ehlers-Danlos syndrome hypermobility type and the excess of affected females: Possible mechanisms and perspectives. Am J Med Genet A. 2010;152A(9):2406\u20138.","journal-title":"Am J Med Genet A"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"39636","DOI":"10.1038\/srep39636","article-title":"Ehlers-Danlos syndrome hypermobility type is associated with rheumatic diseases","volume":"7","author":"Rodgers KR","year":"2017","unstructured":"Rodgers KR, Gui J, Dinulos MB, Chou RC. Ehlers-Danlos syndrome hypermobility type is associated with rheumatic diseases. Sci Rep. 2017;7:39636.","journal-title":"Sci Rep"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"e53646","DOI":"10.2196\/53646","article-title":"Lack of diversity in research on females with Ehlers-Danlos syndromes: Recruitment protocol for a quantitative online survey","volume":"13","author":"Glayzer JE","year":"2024","unstructured":"Glayzer JE, Bray BC, Kobak WH, Steffen AD, Schlaeger JM. Lack of diversity in research on females with Ehlers-Danlos syndromes: Recruitment protocol for a quantitative online survey. JMIR Res Protoc. 2024;13:e53646.","journal-title":"JMIR Res Protoc"},{"issue":"3","key":"ref22","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.mayocpiqo.2024.04.001","article-title":"Phenotypic clusters and multimorbidity in hypermobile Ehlers-Danlos syndrome","volume":"8","author":"Petrucci T","year":"2024","unstructured":"Petrucci T, Barclay SJ, Gensemer C, Morningstar J, Daylor V, Byerly K, et al. Phenotypic clusters and multimorbidity in hypermobile Ehlers-Danlos syndrome. Mayo Clin Proc Innov Qual Outcomes. 2024;8(3):253\u201362.","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1594796","DOI":"10.3389\/fmed.2025.1594796","article-title":"Localized and historical hypermobile spectrum disorders share self-reported symptoms and comorbidities with hEDS and HSD","volume":"12","author":"Fairweather D","year":"2025","unstructured":"Fairweather D, Bruno KA, Darakjian AA, Wilson FC, Fliess JJ, Murphy EF, et al. Localized and historical hypermobile spectrum disorders share self-reported symptoms and comorbidities with hEDS and HSD. Front Med (Lausanne). 2025;12:1594796.","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"ref24","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/PSY.0b013e3181907888","article-title":"Cumulative childhood stress and autoimmune diseases in adults","volume":"71","author":"Dube SR","year":"2009","unstructured":"Dube SR, Fairweather D, Pearson WS, Felitti VJ, Anda RF, Croft JB. Cumulative childhood stress and autoimmune diseases in adults. Psychosom Med. 2009;71(2):243\u201350.","journal-title":"Psychosom Med"},{"issue":"3","key":"ref25","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000328760","article-title":"Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: A consensus proposal","volume":"157","author":"Valent P","year":"2012","unstructured":"Valent P, Akin C, Arock M, Brockow K, Butterfield JH, Carter MC, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: A consensus proposal. Int Arch Allergy Immunol. 2012;157(3):215\u201325.","journal-title":"Int Arch Allergy Immunol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.bbi.2015.07.002","article-title":"Mast cell activation disease: An underappreciated cause of neurologic and psychiatric symptoms and diseases","volume":"50","author":"Afrin LB","year":"2015","unstructured":"Afrin LB, Pohlau D, Raithel M, Haenisch B, Dumoulin FL, Homann J, et al. Mast cell activation disease: An underappreciated cause of neurologic and psychiatric symptoms and diseases. Brain Behav Immun. 2015;50:314\u201321.","journal-title":"Brain Behav Immun"},{"issue":"10","key":"ref27","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1002\/lary.25346","article-title":"Sleep and health implications of snoring: A populational analysis","volume":"125","author":"Bhattacharyya N","year":"2015","unstructured":"Bhattacharyya N. Sleep and health implications of snoring: A populational analysis. Laryngoscope. 2015;125(10):2413\u20136.","journal-title":"Laryngoscope"},{"issue":"1","key":"ref28","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41467-020-14625-1","article-title":"Insights into the aetiology of snoring from observational and genetic investigations in the UK Biobank","volume":"11","author":"Campos AI","year":"2020","unstructured":"Campos AI, Garcia-Marin LM, Byrne EM, Martin NG, Cuellar-Partida G, Renteria ME. Insights into the aetiology of snoring from observational and genetic investigations in the UK Biobank. Nat Commun. 2020;11(1):817.","journal-title":"Nat Commun"},{"issue":"10","key":"ref29","doi-asserted-by":"crossref","first-page":"e2336872","DOI":"10.1001\/jamanetworkopen.2023.36872","article-title":"Prevalence and trends in diagnosed ADHD among US children and adolescents, 2017\u20132022","volume":"6","author":"Li Y","year":"2023","unstructured":"Li Y, Yan X, Li Q, Li Q, Xu G, Lu J, et al. Prevalence and trends in diagnosed ADHD among US children and adolescents, 2017\u20132022. JAMA Netw Open. 2023;6(10):e2336872.","journal-title":"JAMA Netw Open"},{"key":"ref30","doi-asserted-by":"crossref","DOI":"10.15620\/cdc:129520","volume-title":"Diagnosed developmental disabilities in children aged 3\u201317 years: United States, 2019\u20132021","author":"Zablotsky BNA","year":"2023","unstructured":"Zablotsky BNA, Black LI, Blumberg SJ. In: Statistics NCH, editor. Diagnosed developmental disabilities in children aged 3\u201317 years: United States, 2019\u20132021. Hyattsville, MD: NCHS Data Brief; 2023."},{"issue":"10","key":"ref31","doi-asserted-by":"crossref","first-page":"e2442218","DOI":"10.1001\/jamanetworkopen.2024.42218","article-title":"Autism diagnosis among US children and adults, 2011\u20132022","volume":"7","author":"Grosvenor LP","year":"2024","unstructured":"Grosvenor LP, Croen LA, Lynch FL, Marafino BJ, Maye M, Penfold RB, et al. Autism diagnosis among US children and adults, 2011\u20132022. JAMA Netw Open. 2024;7(10):e2442218.","journal-title":"JAMA Netw Open"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"108348","DOI":"10.1016\/j.rmed.2025.108348","article-title":"Unmasking obstructive sleep apnea: Estimated prevalence and impact in the United States","volume":"248","author":"Sonmez I","year":"2025","unstructured":"Sonmez I, Vo Dupuy A, Yu KS, Cronin J, Yee J, Azarbarzin A. Unmasking obstructive sleep apnea: Estimated prevalence and impact in the United States. Respir Med. 2025;248:108348.","journal-title":"Respir Med"},{"issue":"1","key":"ref33","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/head.14024","article-title":"The prevalence and impact of migraine and severe headache in the United States: Updated age, sex, and socioeconomic-specific estimates from government health surveys","volume":"61","author":"Burch R","year":"2021","unstructured":"Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: Updated age, sex, and socioeconomic-specific estimates from government health surveys. Headache. 2021;61(1):60\u20138.","journal-title":"Headache"},{"issue":"10","key":"ref34","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a039172","article-title":"Sex differences in mast cell-associated disorders: A life span perspective","volume":"14","author":"Mackey E","year":"2022","unstructured":"Mackey E, Moeser AJ. Sex differences in mast cell-associated disorders: A life span perspective. Cold Spring Harb Perspect Biol. 2022;14(10).","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref35","volume-title":"Diagnosed allergic conditions in adults: United States, 2021","author":"Ng AEBP","year":"2023","unstructured":"Ng AEBP. In: Statistics NCH, editor. Diagnosed allergic conditions in adults: United States, 2021. Hyattsville, MD: NCHS Data Brief; 2023."},{"issue":"18","key":"ref36","doi-asserted-by":"crossref","first-page":"e180076","DOI":"10.1172\/JCI180076","article-title":"Mechanisms underlying sex differences in autoimmunity","volume":"134","author":"Fairweather D","year":"2024","unstructured":"Fairweather D, Beetler DJ, McCabe EJ, Lieberman SM. Mechanisms underlying sex differences in autoimmunity. J Clin Invest. 2024;134(18):e180076.","journal-title":"J Clin Invest"},{"issue":"1","key":"ref37","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/imr.13191","article-title":"Mast cell ontogeny: From fetal development to life-long health and disease","volume":"315","author":"Chia SL","year":"2023","unstructured":"Chia SL, Kapoor S, Carvalho C, Bajenoff M, Gentek R. Mast cell ontogeny: From fetal development to life-long health and disease. Immunol Rev. 2023;315(1):31\u201353.","journal-title":"Immunol Rev"},{"issue":"46","key":"ref38","doi-asserted-by":"crossref","first-page":"18053","DOI":"10.1073\/pnas.0809479105","article-title":"Brain mast cells link the immune system to anxiety-like behavior","volume":"105","author":"Nautiyal KM","year":"2008","unstructured":"Nautiyal KM, Ribeiro AC, Pfaff DW, Silver R. Brain mast cells link the immune system to anxiety-like behavior. Proc Natl Acad Sci U S A. 2008;105(46):18053\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"ref39","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/exd.13288","article-title":"Neuroendocrinology of mast cells: Challenges and controversies","volume":"26","author":"Theoharides TC","year":"2017","unstructured":"Theoharides TC. Neuroendocrinology of mast cells: Challenges and controversies. Exp Dermatol. 2017;26(9):751\u20139.","journal-title":"Exp Dermatol"},{"issue":"6917","key":"ref40","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nature01324","article-title":"Mast cells in autoimmune disease","volume":"420","author":"Benoist C","year":"2002","unstructured":"Benoist C, Mathis D. Mast cells in autoimmune disease. Nature. 2002;420(6917):875\u20138.","journal-title":"Nature"},{"issue":"2","key":"ref41","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/0891693042000196200","article-title":"Mast cells and innate cytokines are associated with susceptibility to autoimmune heart disease following coxsackievirus B3 infection","volume":"37","author":"Fairweather D","year":"2004","unstructured":"Fairweather D, Frisancho-Kiss S, Gatewood S, Njoku D, Steele R, Barrett M, et al. Mast cells and innate cytokines are associated with susceptibility to autoimmune heart disease following coxsackievirus B3 infection. Autoimmunity. 2004;37(2):131\u201345.","journal-title":"Autoimmunity"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3389\/fncel.2019.00054","article-title":"Mast cells in stress, pain, blood-brain barrier, neuroinflammation and Alzheimer's disease","volume":"13","author":"Kempuraj D","year":"2019","unstructured":"Kempuraj D, Mentor S, Thangavel R, Ahmed ME, Selvakumar GP, Raikwar SP, et al. Mast cells in stress, pain, blood-brain barrier, neuroinflammation and Alzheimer's disease. Front Cell Neurosci. 2019;13:54.","journal-title":"Front Cell Neurosci"},{"issue":"11","key":"ref43","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1007\/s00210-023-02545-y","article-title":"A survey of the currently known mast cell mediators with potential relevance for therapy of mast cell-induced symptoms","volume":"396","author":"Molderings GJ","year":"2023","unstructured":"Molderings GJ, Afrin LB. A survey of the currently known mast cell mediators with potential relevance for therapy of mast cell-induced symptoms. Naunyn Schmiedebergs Arch Pharmacol. 2023;396(11):2881\u201391.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"6","key":"ref44","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.144046","article-title":"Vagal gut-brain signaling mediates amygdaloid plasticity, affect, and pain in a functional dyspepsia model","volume":"6","author":"Cordner ZA","year":"2021","unstructured":"Cordner ZA, Li Q, Liu L, Tamashiro KL, Bhargava A, Moran TH et al. Vagal gut-brain signaling mediates amygdaloid plasticity, affect, and pain in a functional dyspepsia model. JCI Insight. 2021;6(6).","journal-title":"JCI Insight"},{"issue":"3","key":"ref45","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s12016-019-08729-w","article-title":"A review of the contribution of mast cells in wound healing: Involved molecular and cellular mechanisms","volume":"58","author":"Komi DEA","year":"2020","unstructured":"Komi DEA, Khomtchouk K, Santa Maria PL. A review of the contribution of mast cells in wound healing: Involved molecular and cellular mechanisms. Clin Rev Allergy Immunol. 2020;58(3):298\u2013312.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"11","key":"ref46","doi-asserted-by":"crossref","first-page":"6710","DOI":"10.4049\/jimmunol.178.11.6710","article-title":"Cutting Edge: Cross-regulation by TLR4 and T cell Ig mucin-3 determines sex differences in inflammatory heart disease","volume":"178","author":"Frisancho-Kiss S","year":"2007","unstructured":"Frisancho-Kiss S, Davis SE, Nyland JF, Frisancho JA, Cihakova D, Barrett MA, et al. Cutting Edge: Cross-regulation by TLR4 and T cell Ig mucin-3 determines sex differences in inflammatory heart disease. J Immunol. 2007;178(11):6710\u20134.","journal-title":"J Immunol"},{"issue":"49","key":"ref47","doi-asserted-by":"crossref","first-page":"e2303317","DOI":"10.1002\/smll.202303317","article-title":"Reconstituted extracellular vesicles from human platelets decrease viral myocarditis in mice","volume":"19","author":"Beetler DJ","year":"2023","unstructured":"Beetler DJ, Bruno KA, Watkins MM, Xu V, Chekuri I, Giresi P, et al. Reconstituted extracellular vesicles from human platelets decrease viral myocarditis in mice. Small. 2023;19(49):e2303317.","journal-title":"Small"},{"issue":"6","key":"ref48","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jaci.2010.08.035","article-title":"Mast cell activation syndrome: Proposed diagnostic criteria","volume":"126","author":"Akin C","year":"2010","unstructured":"Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: Proposed diagnostic criteria. J Allergy Clin Immunol. 2010;126(6):1099\u2013104. e4.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"ref49","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.anai.2025.03.022","article-title":"Prevalence of mast cell activation disorders and hereditary alpha tryptasemia among patients with postural orthostatic tachycardia syndrome and Ehlers-Danlos syndrome: A systematic review","volume":"135","author":"Farley M","year":"2025","unstructured":"Farley M, Estrada-Mendizabal RJ, Gansert EA, Voelker D, Marks LA, Gonzalez-Estrada A. Prevalence of mast cell activation disorders and hereditary alpha tryptasemia among patients with postural orthostatic tachycardia syndrome and Ehlers-Danlos syndrome: A systematic review. Ann Allergy Asthma Immunol. 2025;135(1):97\u2013102.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"ref50","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jaip.2023.11.041","article-title":"Low prevalence of idiopathic mast cell activation syndrome among 703 patients with suspected mast cell disorders","volume":"12","author":"Zaghmout T","year":"2024","unstructured":"Zaghmout T, Maclachlan L, Bedi N, Gulen T. Low prevalence of idiopathic mast cell activation syndrome among 703 patients with suspected mast cell disorders. J Allergy Clin Immunol Pract. 2024;12(3):753\u201361.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"ref51","first-page":"258","article-title":"The clinical features of hereditary alpha-tryptasemia-implications for interdisciplinary practice","volume":"121","author":"Bubnoff D","year":"2024","unstructured":"von Bubnoff D, Koch D, Stocker H, Ludwig RJ, Wortmann F, von Bubnoff N. The clinical features of hereditary alpha-tryptasemia-implications for interdisciplinary practice. Dtsch Arztebl Int. 2024;121(8):258\u201364.","journal-title":"Dtsch Arztebl Int"},{"issue":"1","key":"ref52","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/bmb\/ldy036","article-title":"Autonomic dysfunction and chronic disease","volume":"128","author":"Zalewski P","year":"2018","unstructured":"Zalewski P, Slomko J, Zawadka-Kunikowska M. Autonomic dysfunction and chronic disease. Br Med Bull. 2018;128(1):61\u201374.","journal-title":"Br Med Bull"},{"issue":"6","key":"ref53","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.jpain.2018.10.008","article-title":"AAPT diagnostic criteria for fibromyalgia","volume":"20","author":"Arnold LM","year":"2019","unstructured":"Arnold LM, Bennett RM, Crofford LJ, Dean LE, Clauw DJ, Goldenberg DL, et al. AAPT diagnostic criteria for fibromyalgia. J Pain. 2019;20(6):611\u201328.","journal-title":"J Pain"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8310986\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8310986\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T18:58:53Z","timestamp":1779217133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8310986\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":53,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-8310986\/v1","relation":{},"subject":[],"published":{"date-parts":[[2026,1,30]]},"subtype":"preprint"}}